Pfizer inks immuno deal

Share this article:
Pfizer emerged from Q3 2013 with a 3% drop in earnings compared to the same period last year
Pfizer emerged from Q3 2013 with a 3% drop in earnings compared to the same period last year

Pfizer and Gliknik inked a deal worth $25 million up front, plus additional milestones that grant Pfizer worldwide rights to the private company's human intravenous immunoglobulin, GL-2045, which may be applied to autoimmune diseases.

FierceBiotech says the treatment in question's “big idea is that its version of FC fusion protein “can be used in much smaller quantities to provide the same or better therapeutic effect than IVIG has.”

Fierce also notes that the treatment bypasses human blood, and could put Pfizer “in a position to make an unlimited quantity to replace what is today a $7 billion product.”

Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.